- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03385707
Hypoglycemia and the Gut Microbiome
October 10, 2023 updated by: Joslin Diabetes Center
This study is designed to evaluate individuals who are currently experiencing symptoms of hypoglycemia, in order to discern correlations between microbiome composition and patterns of postprandial glycemia.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Recent studies have shown that analysis of the gastrointestinal microbiome can be used to predict glycemic response to dietary intake.
Specifically, integrative analysis of dietary consumption, anthropometrics, physical activity and gut microbiota composition can be used to predict postprandial glycemic excursions.
The investigators hypothesize that individualized assessment of glycemic responses to food, together with analysis of the gut microbiome, will allow the design of a personalized dietary approach to minimize glycemic excursions for patients with post-bariatric and other forms of largely postprandial hypoglycemia.
Identification of factors predictive of glycemic excursions and subsequent hypoglycemia may ultimately allow individuals to tailor their diet towards foods which would not induce hypersecretion of insulin and subsequent hypoglycemia.
Study Type
Observational
Enrollment (Estimated)
28
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mary E Patti, MD
- Phone Number: (617) 309-2635
- Email: maryelizabeth.patti@joslin.harvard.edu
Study Contact Backup
- Name: Lauren N Richardson, BS
- Phone Number: (617) 309-4463
- Email: lauren.richardson@joslin.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Joslin Diabetes Center
-
Contact:
- Mary E Patti, MD
- Phone Number: 617-309-2635
- Email: mary.elizabeth.patti@joslin.harvard.edu
-
Principal Investigator:
- Mary E. Patti, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients who experience hypoglycemia after bariatric or other upper gastrointestinal surgery or those with reactive hypoglycemia in the absence of surgery.
Description
Inclusion Criteria
- Males or females diagnosed with ongoing post-bariatric, post-gastric surgery or other forms of postprandial hypoglycemia with prior episodes of neuroglycopenia
- Age 18-65 years of age, inclusive, at screening.
- Willingness to provide informed consent and follow all study procedures, including attending all scheduled visits.
Exclusion Criteria
- Documented hypoglycemia occurring in the fasting state (> 12 hours fast);
- Chronic kidney disease stage 4 or 5 (including end-stage renal disease);
- Hepatic disease, including serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than or equal to 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as serum albumin < 3.0 g/dL; or serum bilirubin > 2.0;
- Congestive heart failure, New York Heart Association (NYHA) class II, III or IV;
- History of myocardial infarction, unstable angina or revascularization within the past 6 months or 2 or more risk factors for coronary artery disease including diabetes, uncontrolled hypertension, uncontrolled hyperlipidemia, and active tobacco use.
- History of syncope (unrelated to hypoglycemia) or diagnosed cardiac arrhythmia
- Concurrent administration of β-blocker therapy;
- History of a cerebrovascular accident;
- Seizure disorder (other than with suspect or documented hypoglycemia);
- Active treatment with any diabetes medications except for acarbose;
- Active treatment with octreotide or diazoxide;
- Active malignancy, except basal cell or squamous cell skin cancers;
- Personal or family history of pheochromocytoma or disorder with increased risk of pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease);
- Known insulinoma;
- Major surgical operation within 30 days prior to screening;
- Hematocrit < 33%;
- Bleeding disorder, treatment with warfarin, or platelet count <50,000;
- Blood donation (1 pint of whole blood) within the past 2 months;
- Active alcohol abuse or substance abuse;
- Current administration of oral or parenteral corticosteroids;
- Pregnancy and/ or lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an intrauterine device (IUD), the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence.
- Use of an investigational drug within 30 days prior to screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
CGM and Microbiota
Participants will wear a Dexcom continuous glucose monitor (CGM) and activity monitor for two weeks.
They will not be aware of sensor glucose values.
A stool sample will be collected.
The investigators will evaluate relationships between patterns of postprandial glycemia, recorded by CGM, food intake, and microbiome composition.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analysis of cumulative duration of hypoglycemia
Time Frame: 2 weeks
|
Duration of hypoglycemia will be assessed by: (1) the number of minutes per day with hypoglycemia, defined as sensor glucose <70 mg/dl, and (2) the number of minutes per day of severe hypoglycemia, defined as sensor glucose <55 mg/dl.
Data will be captured for the entire 24 hour period as well as day and night subsets.
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analysis of frequency of glycemic excursions
Time Frame: 2 weeks
|
Hypoglycemia frequency will be assessed by: (1) number of episodes of hypoglycemia, both moderate (55-70 mg/dl) and severe (<55 mg/dl), (2) number of episodes requiring assistance, and (4) number of episodes of hyperglycemia (>180 mg/dl).
All data will be averaged and reported as episodes per day.
|
2 weeks
|
Impact of activity on glycemic patterns in post-bariatric hypoglycemia
Time Frame: 2 weeks
|
Activity measures (total step number per day) will be analyzed to determine relationship to changes in sensor glucose levels.
Data will be integrated to determine relationships between glycemic patterns, diet, and microbiome.
|
2 weeks
|
Impact of diet on glycemic patterns in post-bariatric hypoglycemia
Time Frame: 2 weeks
|
Dietary information will be transcribed and recorded from participants' food diaries.
Data will be integrated to determine relationships between glycemic patterns, diet, and microbiome.
|
2 weeks
|
Analysis of microbiome in individuals with post-bariatric hypoglycemia
Time Frame: 2 weeks
|
Stool samples will be analyzed to determine microbiome community by 18S sequencing.
Data will be integrated to determine relationships between glycemic patterns, diet, and microbiome.
|
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mary E Patti, MD, Joslin Diabetes Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Patti ME, Goldfine AB. The rollercoaster of post-bariatric hypoglycaemia. Lancet Diabetes Endocrinol. 2016 Feb;4(2):94-6. doi: 10.1016/S2213-8587(15)00460-X. Epub 2015 Dec 15. No abstract available.
- Mulla CM, Middelbeek RJW, Patti ME. Mechanisms of weight loss and improved metabolism following bariatric surgery. Ann N Y Acad Sci. 2018 Jan;1411(1):53-64. doi: 10.1111/nyas.13409. Epub 2017 Sep 3.
- Suhl E, Anderson-Haynes SE, Mulla C, Patti ME. Medical nutrition therapy for post-bariatric hypoglycemia: practical insights. Surg Obes Relat Dis. 2017 May;13(5):888-896. doi: 10.1016/j.soard.2017.01.025. Epub 2017 Jan 16.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 7, 2019
Primary Completion (Estimated)
September 1, 2024
Study Completion (Estimated)
September 1, 2024
Study Registration Dates
First Submitted
December 7, 2017
First Submitted That Met QC Criteria
December 20, 2017
First Posted (Actual)
December 28, 2017
Study Record Updates
Last Update Posted (Actual)
October 11, 2023
Last Update Submitted That Met QC Criteria
October 10, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-28
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypoglycemia
-
University of UlmRecruitingHypoglycemia, ReactiveGermany
-
University of ArizonaNot yet recruiting
-
Milton S. Hershey Medical CenterDexCom, Inc.; Children's Miracle NetworkRecruiting
-
Zealand University HospitalUnknownHypoglycemia, ReactiveDenmark
-
MBX BiosciencesProSciento, Inc.RecruitingPostbariatric HypoglycemiaUnited States
-
University Hospital, Basel, SwitzerlandBoehringer IngelheimRecruitingPostprandial HypoglycemiaSwitzerland
-
University of NebraskaCompletedNeonatal HypoglycemiaUnited States
-
Vogenx, Inc.CompletedPostbariatric HypoglycemiaUnited States
-
Stanford UniversityCompletedNeonatal HypoglycemiaUnited States
-
Diva De LeonLester and Liesel Baker FoundationCompletedPostprandial HypoglycemiaUnited States
Clinical Trials on Dexcom continuous glucose monitor and activity monitor
-
Boston Children's HospitalCompleted
-
Woman'sDexCom, Inc.Active, not recruitingGestational Diabetes Mellitus in PregnancyUnited States
-
University of California, San DiegoDexCom, Inc.Recruiting
-
MemorialCare Health SystemDexCom, Inc.RecruitingHyperinsulinism | Hypoglycemia NeonatalUnited States
-
The Cleveland ClinicDexCom, Inc.Active, not recruitingSurgery--ComplicationsUnited States
-
University of Massachusetts, WorcesterNot yet recruiting
-
University of California, San FranciscoDexCom, Inc.RecruitingInsulin Resistance | Dysglycemia | PCOS (Polycystic Ovary Syndrome) of Bilateral OvariesUnited States
-
University of California, IrvineDexCom, Inc.Active, not recruitingDiabetes | Hemodialysis | Glucose MeasurementUnited States
-
HealthPartners InstituteThe Leona M. and Harry B. Helmsley Charitable TrustCompletedType 1 DiabetesUnited States
-
Vanderbilt University Medical CenterRecruitingDuchenne Muscular DystrophyUnited States